I
mproved understanding of the primary molecular events underlying NIDDM and obesity is essential if more effective therapies are to be devised. Individual susceptibility to these interrelated conditions is under genetic influence (1) , and clues to the identity of the major aetiological genes may come from physiological studies that pinpoint candidate pathways. A characteristic feature of NIDDM and certain prediabetic states, such as gestational diabetes mellitus (GDM), is a marked increase in the proportion of circulating insulin precursor molecules (proinsulin and split proinsulin intermediates) (2, 3) . Release of disproportionate amounts of these biologically inactive precursors may contribute to the relative insulin deficiency apparent in GDM and NIDDM (2) .
The processing of proinsulin to mature insulin is catalyzed by prohormone convertase (PC) enzymes active in (3-cell granules. PCI (also named PC3) cleaves intact proinsulin to produce 32,33 split proinsulin. PC2 and carboxypeptidase E (CPE) catalyze subsequent reactions (4) . Functional defects in any of these candidate genes could contribute to the NIDDM phenotype.
Furthermore, recent studies indicate a role for these loci in the determination of obesity. Mutations in the Cpe gene resulting in absent enzyme activity in islets and pituitary underlie the phenotype of the fat/fat mouse (5). More recently, Jackson et al. (6) reported on a family segregating two distinctPCi mutations. The mother was a compound heterozygote who had presented with childhood obesity, GDM, and a variety of endocrine abnormalities attributable to defective prohormone processing. In this report, we have sought to establish whether variation in the PCI gene contributes to typical NIDDM, GDM, and obesity.
First, we sought evidence for linkage between the PCI gene region and NIDDM in 26 families (13 European, 10 South Asian Indian, 3 Black-Caribbean) ascertained in London, Newcastle-upon-Tyne, and Malaysia, hi all families, at least three members were diabetic (7) . Median (range) BMI for the diabetic individuals was 27.2 (18.2-50.0) kg/m 2 . The Genebridge 4 radiation hybrid panel was used to localize the PCI gene to a 4-cM interval between AFM205wg7 and GATA48A11 on chromosome 5q (logarithm of odds [LOD] score >3) by polymerase chain reaction (PCR) amplification of sequences in exons 8 and 11 (8) . We selected five microsatellite markers spanning a 15-cM region of chromosome 5ql5-21 centered on PCI (Table 1) : D5S401-7 cMAFM205wg7-4 cM-GATA48All-2 cM-D5S409-2 CM-D5S433. Primer sequences and interlocus distances were taken from Genethon (9) and Whitehead (version 11.9) databases (10). Genotypes were determined by acrylamide gel electrophoresis after radioactive PCR (using [
S]dATP).
In the absence of a validated segregation model for NIDDM, we report the multipoint, nonparametric results obtained with GENEHUNTER (Table 1) . Marker allele frequencies were estimated from founders and were similar for all ethnic groups. We found no evidence for excess allele-sharing in the region: the maximum nonparametric linkage (NPL) score obtained was 0.24 at D5S409. Reanalysis, after subdivision by pedigree origin, did not indicate ethnic heterogeneity (additional information about this subject can be found in the on-line appendix at www.diabetes.org/diabetes/appendix.htm).
As linkage analysis is insensitive to minor genetic effects, we screened the PCI -coding region to determine the prevalence of novel and previously reported variant sequences. We examined four subject groups:
1. From the families described, 80 diabetic individuals, 25 unaffected spouses, and 10 nondiabetic family members with the highest proinsulin levels (11) were examined.
2. Nondiabetic subjects with high intactsplit proinsulin levels recruited from the population-based Isle of Ely Diabetes Study (12) were studied, and of 1,071 glucose-tolerant individuals surveyed, we selected 17 with the highest fasting intact:32,33 split proinsulin ratio (13 All 14 exons were amplified using published primer sequences and conditions (8) and variants were sought using heteroduplex and single-strand conformation polymorphism (SSCP) analyses. For heteroduplex analysis, PCR products were denatured, cooled to room temperature, and electrophoresed on 0.5 X MDE gels (Flowgen, Iichfield, UK). For SSCP analysis, denatured PCR products were electrophoresed on 10% nondenaturing polyacrylamide gels at 4°C and 25°C. Known variants in the glucokinase and uncoupling protein (UCP1) genes were reliably detected by both methods, as was the previously described exon 14 polymorphism (8) . No novel sequence variants were detected in any population group.
The study groups were also tested explicitly for four known PCI variants. Two of these variants (Arg/Gln 53 in exon 2 and Gln/Glu 638 in exon 14) had been described in Japanese populations (8) ; the others (the intron 5 splice donor site A->C +4 and Gly/Arg 483 in exon 13) were first described by Jackson et al. (6) . PCR-restriction fragment length polymorphism (RFLP) analyses were used to genotype for Arg/Gln 53 (loss of a Taq I site), Gly/Arg 483 (loss of Ma IV site) and Gln/Glu 638 Qoss of ScrFl site). The intron 5 variant altered no restriction sites, so we developed a robust SSCP assay (primers 5'-TGTCTCTTTTAGGATCCAGAGGC-3' and 5' -CTTTATTTCACACAAATGCATATTGA-3' ). The Arg/Gln 53 , Gly/Arg 483 , and intron 5 variants were not seen in any subject studied. The exon 14 variant was found in -20% of chromosomes in each study cohort (37 of 160 from affected family members, 11 of 50 from unaffected spouses, 4 of 20 from hyperproinsulinemic relatives, 8 of 34 from Ely subjects, 5 of 24 from GDM subjects, and 5 of 20 from obese, diabetic subjects from the Warren 2 collection) and each ethnic group. These prevalences are similar to those reported in Japanese diabetic and control groups (24 and 22%, respectively) (8).
Our findings fail to support a role for variation in the PCI gene in determining susceptibility to obesity, GDM, and NIDDM in the populations studied. No evidence for excess allele-sharing was observed in our dataset. We note that there have been no reports of linkage in this region in genomewide scans for NIDDM (14, 15) . Absence of evidence for linkage does not exclude the possibility that variants in the gene contribute to a minority of cases of diabetes and/or obesity. The populations chosen for mutation detection were enriched with individuals considered most likely to have PCI mutations through a combination of clinical features, family history, and physiological measurements. Nonetheless, no novel mutations were found. Furthermore, previously described polymorphisms were not overrepresented among affected individuals, confirming and extending the findings of other groups (6, 8) .
We conclude that the alterations in insulin processing observed in prediabetic and diabetic populations are not due to variation in the coding regions of the PCI gene. The possibility that etiological variants lie outside the screened regions (e.g., cryptic splice sites or regulatory mutations) will require exploration in subsequent studies.
